ZS Pharma racks up $55 mln in Series D funds
ZS Pharma has raised $55 million in Series D financing. Novo A/S led the round with participation from RA Capital, Adage Capital, Sofinnova Ventures, Alta Partners, Devon Park Bioventures, 3x5 Special Opportunity Fund, Salem Partners and RiverVest. Based in Coppell, Texas, ZS Pharma is a specialty pharmaceutical company focused on treating kidney, cardiovascular and liver disorders.
6 March 2014•2 mins read
